Despite these successes and the multiple tumor-associated mutations resulting in activation of MEK, clinical benefit to MEK inhibitors has been relatively modest, particularly in the context of tumors harboring mutant RAS [8]. This evidence concerns the gene MAP2K7 and neoplasm.